Lao-Tzu S. Allan-Blitz, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Gonorrhea | 19 | 2024 | 355 | 7.780 |
Why?
|
Neisseria gonorrhoeae | 19 | 2025 | 249 | 7.240 |
Why?
|
Ciprofloxacin | 12 | 2023 | 313 | 3.910 |
Why?
|
DNA Gyrase | 8 | 2023 | 86 | 3.260 |
Why?
|
Sexually Transmitted Diseases | 6 | 2025 | 668 | 3.160 |
Why?
|
Syphilis | 5 | 2024 | 243 | 2.440 |
Why?
|
Sexually Transmitted Diseases, Bacterial | 3 | 2024 | 31 | 2.320 |
Why?
|
Drug Resistance, Bacterial | 15 | 2025 | 1063 | 2.300 |
Why?
|
Homosexuality, Male | 10 | 2024 | 1344 | 2.290 |
Why?
|
Anti-Bacterial Agents | 19 | 2025 | 7472 | 1.980 |
Why?
|
Post-Exposure Prophylaxis | 3 | 2024 | 113 | 1.950 |
Why?
|
Chlamydia Infections | 4 | 2024 | 365 | 1.650 |
Why?
|
Microbial Sensitivity Tests | 10 | 2023 | 1963 | 1.470 |
Why?
|
HIV Infections | 13 | 2024 | 17589 | 1.210 |
Why?
|
Pharynx | 3 | 2018 | 436 | 1.040 |
Why?
|
Point-of-Care Systems | 3 | 2024 | 1240 | 0.940 |
Why?
|
Doxycycline | 2 | 2024 | 349 | 0.940 |
Why?
|
Treponema pallidum | 1 | 2024 | 48 | 0.920 |
Why?
|
Anal Canal | 2 | 2017 | 375 | 0.920 |
Why?
|
Los Angeles | 7 | 2021 | 245 | 0.900 |
Why?
|
Mycoplasma genitalium | 2 | 2025 | 13 | 0.870 |
Why?
|
Sexual Partners | 4 | 2023 | 807 | 0.830 |
Why?
|
Monkeypox virus | 1 | 2022 | 43 | 0.820 |
Why?
|
Sexual Behavior | 6 | 2023 | 2200 | 0.820 |
Why?
|
Antibodies, Bacterial | 3 | 2024 | 1478 | 0.800 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2024 | 340 | 0.790 |
Why?
|
Syphilis Serodiagnosis | 2 | 2019 | 37 | 0.780 |
Why?
|
Immunoglobulin M | 2 | 2024 | 1528 | 0.760 |
Why?
|
Drug Resistance, Microbial | 1 | 2023 | 829 | 0.710 |
Why?
|
Azithromycin | 2 | 2018 | 201 | 0.690 |
Why?
|
Community Health Centers | 1 | 2023 | 469 | 0.670 |
Why?
|
Chlamydia trachomatis | 4 | 2025 | 239 | 0.670 |
Why?
|
Disease Outbreaks | 3 | 2023 | 1761 | 0.660 |
Why?
|
Proctitis | 1 | 2019 | 40 | 0.650 |
Why?
|
Sex Offenses | 1 | 2023 | 357 | 0.620 |
Why?
|
World Health Organization | 1 | 2024 | 1327 | 0.610 |
Why?
|
Asymptomatic Infections | 1 | 2019 | 135 | 0.610 |
Why?
|
Mycoplasma Infections | 1 | 2018 | 120 | 0.610 |
Why?
|
Anti-Infective Agents | 2 | 2023 | 984 | 0.600 |
Why?
|
Medical History Taking | 1 | 2022 | 779 | 0.600 |
Why?
|
Coxiella burnetii | 1 | 2018 | 37 | 0.600 |
Why?
|
Q Fever | 1 | 2018 | 38 | 0.590 |
Why?
|
Prisoners | 1 | 2021 | 316 | 0.590 |
Why?
|
AIDS Serodiagnosis | 1 | 2019 | 220 | 0.580 |
Why?
|
Treatment Failure | 1 | 2024 | 2663 | 0.570 |
Why?
|
Meningitis, Bacterial | 1 | 2018 | 225 | 0.520 |
Why?
|
Peru | 5 | 2023 | 891 | 0.510 |
Why?
|
Epidemics | 1 | 2021 | 517 | 0.500 |
Why?
|
Genotype | 6 | 2019 | 13048 | 0.500 |
Why?
|
Immunoassay | 1 | 2018 | 746 | 0.470 |
Why?
|
Ceftriaxone | 3 | 2022 | 175 | 0.460 |
Why?
|
Endocarditis, Bacterial | 1 | 2018 | 436 | 0.460 |
Why?
|
Humans | 56 | 2025 | 768887 | 0.440 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2022 | 2203 | 0.430 |
Why?
|
Anti-HIV Agents | 3 | 2024 | 4576 | 0.420 |
Why?
|
Papillomavirus Infections | 1 | 2024 | 1640 | 0.410 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2023 | 4356 | 0.390 |
Why?
|
Cefixime | 2 | 2022 | 13 | 0.380 |
Why?
|
Tuberculosis | 1 | 2024 | 2029 | 0.370 |
Why?
|
California | 3 | 2021 | 1443 | 0.360 |
Why?
|
Ultrasonography | 1 | 2024 | 6001 | 0.360 |
Why?
|
Sensitivity and Specificity | 5 | 2024 | 14751 | 0.360 |
Why?
|
Florida | 2 | 2022 | 430 | 0.350 |
Why?
|
Seroepidemiologic Studies | 2 | 2021 | 405 | 0.340 |
Why?
|
Practice Guidelines as Topic | 2 | 2024 | 7460 | 0.340 |
Why?
|
Cephalosporins | 2 | 2024 | 200 | 0.340 |
Why?
|
Cities | 2 | 2022 | 543 | 0.330 |
Why?
|
Poverty | 1 | 2021 | 2720 | 0.320 |
Why?
|
Prevalence | 8 | 2021 | 15875 | 0.310 |
Why?
|
Health Promotion | 1 | 2019 | 2210 | 0.290 |
Why?
|
Pediatrics | 1 | 2022 | 3628 | 0.290 |
Why?
|
Primary Health Care | 1 | 2024 | 4748 | 0.280 |
Why?
|
DNA, Bacterial | 2 | 2024 | 1478 | 0.280 |
Why?
|
Polymerase Chain Reaction | 3 | 2022 | 6085 | 0.280 |
Why?
|
Health Services Accessibility | 1 | 2024 | 5520 | 0.270 |
Why?
|
Unsafe Sex | 2 | 2019 | 239 | 0.270 |
Why?
|
Urethritis | 1 | 2024 | 30 | 0.240 |
Why?
|
Syphilis, Congenital | 1 | 2024 | 26 | 0.240 |
Why?
|
Male | 21 | 2024 | 365249 | 0.240 |
Why?
|
Pandemics | 2 | 2021 | 8745 | 0.230 |
Why?
|
Rectum | 2 | 2019 | 900 | 0.220 |
Why?
|
TNF Receptor-Associated Factor 2 | 1 | 2023 | 56 | 0.210 |
Why?
|
Leukotriene E4 | 1 | 2023 | 75 | 0.210 |
Why?
|
Early Detection of Cancer | 1 | 2017 | 3238 | 0.210 |
Why?
|
Adult | 15 | 2024 | 223818 | 0.200 |
Why?
|
Mass Screening | 4 | 2019 | 5455 | 0.190 |
Why?
|
Female | 18 | 2024 | 397464 | 0.180 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2024 | 620 | 0.170 |
Why?
|
New York City | 1 | 2021 | 737 | 0.160 |
Why?
|
Young Adult | 7 | 2023 | 60110 | 0.160 |
Why?
|
Behavioral Risk Factor Surveillance System | 1 | 2019 | 211 | 0.150 |
Why?
|
Hepatitis B, Chronic | 1 | 2023 | 413 | 0.150 |
Why?
|
Long-Term Care | 1 | 2022 | 632 | 0.150 |
Why?
|
Cytokines | 2 | 2023 | 7453 | 0.150 |
Why?
|
Saliva | 1 | 2022 | 855 | 0.150 |
Why?
|
Asymptomatic Diseases | 1 | 2021 | 590 | 0.150 |
Why?
|
Hepatitis B | 1 | 2023 | 711 | 0.140 |
Why?
|
Antigens, Viral | 1 | 2021 | 996 | 0.140 |
Why?
|
Behavior Therapy | 1 | 2023 | 886 | 0.140 |
Why?
|
Mentors | 1 | 2022 | 672 | 0.140 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2018 | 239 | 0.140 |
Why?
|
Microbiological Techniques | 1 | 2017 | 97 | 0.140 |
Why?
|
ROC Curve | 1 | 2024 | 3629 | 0.130 |
Why?
|
RNA, Bacterial | 1 | 2018 | 393 | 0.130 |
Why?
|
Demography | 1 | 2021 | 1643 | 0.130 |
Why?
|
Macrolides | 1 | 2017 | 205 | 0.130 |
Why?
|
Retrospective Studies | 7 | 2024 | 81892 | 0.120 |
Why?
|
Codon | 1 | 2017 | 599 | 0.120 |
Why?
|
Fluoroquinolones | 1 | 2017 | 309 | 0.120 |
Why?
|
Interferon-gamma | 1 | 2023 | 3163 | 0.120 |
Why?
|
Cervix Uteri | 1 | 2018 | 576 | 0.120 |
Why?
|
Employment | 1 | 2021 | 1114 | 0.120 |
Why?
|
Hydroxychloroquine | 1 | 2018 | 426 | 0.110 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2018 | 1048 | 0.110 |
Why?
|
Cross-Sectional Studies | 4 | 2021 | 26384 | 0.110 |
Why?
|
Transsexualism | 1 | 2017 | 210 | 0.110 |
Why?
|
Infant, Newborn | 2 | 2024 | 26394 | 0.110 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2023 | 1903 | 0.110 |
Why?
|
Anus Neoplasms | 1 | 2017 | 336 | 0.110 |
Why?
|
Social Stigma | 1 | 2019 | 788 | 0.100 |
Why?
|
Medical Records | 1 | 2018 | 1411 | 0.100 |
Why?
|
Adolescent | 5 | 2021 | 89247 | 0.100 |
Why?
|
Cohort Studies | 3 | 2021 | 41800 | 0.100 |
Why?
|
Costs and Cost Analysis | 1 | 2018 | 1669 | 0.100 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2024 | 3411 | 0.100 |
Why?
|
HIV Antibodies | 1 | 2018 | 1341 | 0.090 |
Why?
|
Incidence | 2 | 2021 | 21545 | 0.090 |
Why?
|
Colonoscopy | 1 | 2019 | 1410 | 0.090 |
Why?
|
Drug Utilization | 1 | 2017 | 1191 | 0.090 |
Why?
|
Thoracic Vertebrae | 1 | 2015 | 614 | 0.090 |
Why?
|
Massachusetts | 1 | 2024 | 8888 | 0.090 |
Why?
|
Boston | 1 | 2023 | 9375 | 0.090 |
Why?
|
HIV | 1 | 2017 | 1596 | 0.090 |
Why?
|
Drug Therapy, Combination | 1 | 2019 | 6320 | 0.080 |
Why?
|
Insurance Coverage | 1 | 2021 | 1946 | 0.080 |
Why?
|
Vaccination | 1 | 2021 | 3436 | 0.080 |
Why?
|
Curriculum | 1 | 2022 | 3782 | 0.080 |
Why?
|
Insurance, Health | 1 | 2021 | 2518 | 0.080 |
Why?
|
Scoliosis | 1 | 2015 | 793 | 0.080 |
Why?
|
Public Health | 1 | 2021 | 2680 | 0.070 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2024 | 9081 | 0.070 |
Why?
|
Predictive Value of Tests | 1 | 2024 | 15471 | 0.070 |
Why?
|
Middle Aged | 6 | 2023 | 223740 | 0.070 |
Why?
|
United States | 3 | 2021 | 73180 | 0.070 |
Why?
|
Mutation | 4 | 2023 | 30266 | 0.070 |
Why?
|
Immunoglobulin G | 1 | 2018 | 4568 | 0.070 |
Why?
|
Internet | 1 | 2018 | 3112 | 0.060 |
Why?
|
Bacterial Proteins | 1 | 2019 | 3839 | 0.060 |
Why?
|
Age Factors | 1 | 2021 | 18454 | 0.060 |
Why?
|
Emergency Service, Hospital | 1 | 2024 | 7956 | 0.060 |
Why?
|
Child | 2 | 2022 | 80969 | 0.050 |
Why?
|
Risk Factors | 2 | 2021 | 74971 | 0.050 |
Why?
|
Sierra Leone | 1 | 2023 | 171 | 0.050 |
Why?
|
Genitalia | 1 | 2023 | 113 | 0.050 |
Why?
|
Hospitals, Public | 1 | 2023 | 204 | 0.050 |
Why?
|
Genomics | 1 | 2017 | 5928 | 0.050 |
Why?
|
Serine-Type D-Ala-D-Ala Carboxypeptidase | 1 | 2019 | 16 | 0.040 |
Why?
|
Hepatitis B virus | 1 | 2023 | 533 | 0.040 |
Why?
|
Molecular Epidemiology | 1 | 2017 | 473 | 0.030 |
Why?
|
Prospective Studies | 1 | 2017 | 54950 | 0.030 |
Why?
|
Liver Cirrhosis | 1 | 2023 | 1962 | 0.030 |
Why?
|
Rural Population | 1 | 2023 | 2322 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 2015 | 1321 | 0.020 |
Why?
|
Aged | 1 | 2021 | 171790 | 0.020 |
Why?
|
Gene Expression | 1 | 2017 | 7602 | 0.010 |
Why?
|